Owen Mumford, a specialist in the design, manufacture and advancement of medical devices, has been awarded B Corp certification after demonstrating compliance to the requirements of this mark.
Owen Mumford, which established its sustainability programme in 2014 and has formally committed to the UN’s Sustainable Development Goals (SDGs), now joins a respected community of for-profit businesses that are applying growth and profit to the positive gain of the environment and external communities, as well as employees.
B Corp certification assesses five areas of impact: governance, community, workers, environment and customers.
Jarl Severn, CEO at Owen Mumford, said: “Our social and environmental responsibilities have always been high on the agenda at Owen Mumford. Submitting ourselves to the rigorous process of B Corp certification is a natural development of our core principles. Companies like ours that operate in the medical sector are used to the demands of a tightly regulated environment. We believe that it is not enough simply to state ethical and environmental aspirations, but it is also critical to achieve a recognised certification. After all, our marketplaces are reliant on top ethical standards to protect environments, professionals and patients. B Corp provides a solid benchmark for continually improving what we do in our business, in the global communities that we are part of and the ones where can make a positive impact.”
Owen Mumford has designed and manufactured medical devices in self-injection, blood sampling and drug delivery for almost 70 years. This milestone firmly underscores its commitment to making a positive difference on social and environmental impact.
Kate Sandle, director of programmes and engagement of B Lab UK, said: “We are delighted to welcome Owen Mumford to the B Corp community. This is a movement of companies who are committed to changing how business operates and believe business really can be a force for good. We know that Owen Mumford is going to be a fantastic addition to the community and will continue driving the conversation forward. Welcoming Owen Mumford is an exciting moment because it has an opportunity to lead the way within the medical device industry.”
